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Chimeras are individuals with tissues derived frommore than one zygote. Interspecific chimeras have
tissues derived from different species. The biological consequences of human-animal chimeras have
become an issue of ethical debate. Ironically, human-animal chimeras with human blood, neurons,
germ cells, and other tissues have been generated for decades. This has facilitated human biological
studies and therapeutic strategies for disease.Introduction
A chimera is an individual composed of somatic and, in
certain cases, germline tissues derived from more than
one zygote. There are different ways to generate tissue
chimerism, including mixing embryonic cells from two in-
dividuals, transplanting fetal or adult tissues from one indi-
vidual into another individual, or grafting embryonic stem
(ES) cells or their differentiated products into another indi-
vidual. For example, two genetically distinct 8 cell mouse
preimplantation embryos whose zona pellucidae have
been removed can be pushed together in a tissue culture
dish and then grown in vitro to form a single blastocyst.
Transfer of this blastocyst into the uterus of a foster
mother often results in a mouse with somatic and germ
cells of both genotypes, a so-called aggregation chimera.
Tissue chimerism can also result from clinical treatments
of disease. A patient who receives a successful tissue or
organ transplant (e.g., bone marrow) would likely have
the adult donor tissues obtained from a genetically distinct
individual, i.e., such a patient would be a bonemarrow chi-
mera. If the donor tissue and recipient are of different spe-
cies, then an interspecific or cross-species chimera is
generated. Human-animal interspecific chimeras have
been created by grafting human cells and tissues into
the embryos, fetuses, or adults of vertebratemodel organ-
isms. The derivation of human embryonic stem (hES) cells
has created the opportunity to use these pluripotent cells
to generate human-animal chimeras that has led to recent
ethical discussions (McLaren, 2007). These ethical issues
are discussed in the accompanying articles by Hyun et al.
(2007) and Lensch et al. (2007).
Laboratory animals are routinely used to model human
biology and disease but are not human and therefore can-
not fully replicate human physiology. Thus, the primary
goal of human-animal chimera research is to produce hu-
man cellular characters in animals. The animal carrying the
human tissue can then be examined or treated to investi-
gate human-specific biological processes and disease
without experimentation on human individuals. The gen-
eral public and most scientists may not realize that hu-
man-animal chimeras have been routinely produced for
decades and are generated daily in biomedical researchlaboratories throughout the world. Here we review differ-
ent types of human-animal chimeras that have been
used in biomedical research. We focus our review on
human-animal chimeras generated by transplanting hu-
man tissues into vertebrates, predominantly rodent
models. These different types of human-animal chimeras
have provided important insights into fundamental biolog-
ical mechanisms and the development of therapeutic
protocols for human disease.
Xenografts into Immune-Deficient Animals
Human-animal chimeras are typically generated by graft-
ing human cells or tissues orthotopically or heterotopically
into an immune-deficient animal. The host may be a fetus
whose immune system is immature and has yet to estab-
lish ‘‘self’’ or a postnatal animal with a genetic mutation
that causes the loss of specific immune system compo-
nents. Engraftment of human cells into wild-type postnatal
animals whose immune systems have been established
can also be accomplished by immunosuppression with
drugs (e.g., cyclosporin).
Classically, the immune-deficient athymic nude mouse
has been used for decades as a recipient for human tissue
grafts to generate human-mouse chimeras. Nude (Foxn1)
is a recessivemutation that results in, among other pheno-
types, loss of T cells. This T cell deficiency in the nude
mouse is sufficient to allow many types of xenograft tis-
sues to survive and grow, including different types of nor-
mal fetal and adult human tissues (Povlsen et al., 1974).
Abnormal or diseased human tissues can also be trans-
planted into animals. The successful growth of human
tumors in animals was pioneered by transplantation into
immune-privileged sites (e.g., the rabbit or guinea pig
anterior chamber of the eye or Syrian hamster cheek
pouch). The advent of the nude mouse greatly facilitated
these types of studies, and indeed, this in vivo assay
is one of the fundamental experimental paradigms for
cancer research (Rygaard and Povlsen, 1969). Pieces of
human tumors are grafted under the skin of nude mice
providing a bioincubator for tumor growth. The mouse
essentially becomes a cancer patient whose tumor can
then bemanipulated in various ways to understand cancerCell Stem Cell 1, September 2007 ª2007 Elsevier Inc. 259
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Although nude mice are sufficient for many types of
xenograft experiments, their immune systems still have
B cells and natural killer (NK) cells and are able to fix com-
plement, and thus are capable of hindering the engraft-
ment of some types of human tissues, notably hemato-
poietic cells. Mutations in Prkdc (scid, severe combined
immunodeficiency), Lyst (beige), Btk (xid, X-linked immu-
nodeficient), B2m (b2 microglobulin), Prf1 (perforin), Ilr2g
(IL-2 receptor g), and Rag1 and Rag2 mice have also
been used singly or in various combinations to further in-
activate other components of the host immune system
(Shultz et al., 2007). In addition, genetic background can
also influence host immune function. Mice on the nonob-
ese diabetic (NOD) inbred genetic background combined
with the Prkdcscid mutation (NOD-SCID) show greater hu-
man hematopoietic cell engraftment than classical SCID
mice. More recently, NOD-SCID with Ilr2g and some of
the above mutations have shown the greatest human he-
matopoietic cell transplant contributions. Human-mouse
chimeras with tissues engrafted at orthotopic sites have
been termed ‘‘humanized.’’ The utility of human-mouse
hematopoietic chimeras has been recently reviewed
(Shultz et al., 2007).
Another general approach to generate human-animal
chimeras is to add other mutations to or chemically treat
or irradiate immune-compromised (e.g., nude, SCID,
etc.) animals to make them also deficient for nonimmune
system tissues. The deficient or absent tissue opens
a niche for the engrafted human nonimmune system cells.
For example, sublethal irradiation of NOD-SCID mice is
necessary to ‘‘knock down’’ host hematopoiesis for en-
graftment of human hematopoietic stem cells. Using this
general approach, human tissues can contribute signifi-
cantly or completely to a specific tissue or organ in the an-
imal. Many of the grafted human tissues have significant
regenerative potential and long-term colonizing ability
(i.e., stem cells), whereas other tissues can only terminally
differentiate (e.g., ovarian primordial follicles).
Mice with Human Livers
Human liver and disease have been studied in human-
mouse chimeras (Kneteman and Mercer, 2005). This field
was enabled by the discovery that the expression of an al-
bumin-urokinase plasminogen activator (Alb-uPA) trans-
gene in the mouse is hepatotoxic, resulting in the progres-
sive destruction of the mouse liver. Transplantation of
primary mouse hepatocytes into immune-compatible
Alb-uPA transgenic mice was found to be capable of re-
constituting the host liver, highlighting the tremendous re-
generative capacity of hepatocytes. It was subsequently
shown that rat hepatocytes could also successfully recon-
stitute the liver of nude Alb-uPA transgenic mice. This liver
reconstitution mousemodel has led to the development of
micewith livers reconstituted by engrafted human hepato-
cytes. Another strategy to generate human-mouse chi-
meras is to place primary human hepatocytes in a matrix
followed by engraftment under the mouse kidney capsule.260 Cell Stem Cell 1, September 2007 ª2007 Elsevier Inc.These human-mouse chimera models have been useful
for studying human hepatitis virus infections and human
liver-specific metabolic responses to drugs.
Animals with Human Neurons
Among the most ethically charged forms of human-animal
chimerism are those that incorporate human neurons into
the host central nervous system (CNS). Human-animal
neural chimeras have been generated in two fundamental
ways: (1) human fetal brain cells are used directly, cultured
as neurospheres to isolate neural stem/progenitor cells, or
sorted using cell surface markers and transplanted into
embryonic or newborn animals; (2) hES cells are differen-
tiated into neural precursor cells or differentiated neurons
in vitro and then transplanted into embryonic, newborn, or
adult animals. The site of transplantation is typically a brain
ventricle, providing the graft access to large areas of the
CNS, but these cells can also be transplanted directly
into host neural tissue.
Extensive neural and glial brain chimerism was docu-
mented using human fetal brain tissue transplanted di-
rectly, as a single cell suspension, or first cultured in vitro
as a monolayer or as neurospheres, into the cerebral brain
vesicles of wild-type fetal rats (Bru¨stle et al., 1998). Human
fetal brain tissue has also been dissociated and then
sorted for human central nervous system stem cell
(hCNS-SC) activity, using antibodies that enrich for
hematopoietic stem cells (Uchida et al., 2000). These
hCNS-SCs were subsequently cultured to generate neu-
rospheres, then dissociated and injected into the lateral
ventricles of newborn NOD-SCID mouse brains. Differen-
tiated human neurons were found throughout the brains of
these human-mouse neural chimeras up to 7 months
posttransplant. To investigate the ability of human fetal
brain cells to engraft a primate brain, human-monkey chi-
meras have been generated by transplantation of human
fetal neural stem cells into the lateral brain ventricles of
fetal monkeys (Ourednik et al., 2001). Analysis of the
host brains 1 month posttransplantation revealed the
presence of human neurons and glia and undifferentiated
donor cells.
hES cells have also been a source of neural progenitors
and differentiated neurons to test their ability to incorpo-
rate into a developing or mature animal CNS. hES cells
were cultured to generate neural cells and transplanted
into the cerebral ventricles of wild-type newborn mouse
brain immune suppressed with cyclosporin (Zhang et al.,
2001). The grafted human cells were found in multiple re-
gions of the host brain and had differentiated into neurons
and glia. Like mouse ES cells, hES cells can now be di-
rected in vitro to specific neuronal fates. Recently, hES
cell-derived motor neurons generated in vitro were trans-
planted into the spinal cords of chick embryos and adult
rat spinal cord (Lee et al., 2007). The human motor neu-
rons were able to quickly incorporate into the spinal
cord of the chick embryo, retain motor neuron markers,
and extend axons from the spinal cord to peripheral tis-
sues (i.e., muscles). The human motor neuron grafts into
the adult rat spinal cords were able to survive for up to
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The sum of these findings on human-animal neural chi-
meras is that human neural cells can incorporate into the
host animal CNS, differentiate into specific neuronal sub-
classes, and execute neuronal functions. This raises the
possibility of using human-animal neural chimeras for
studies of human neural development, neurodegenerative
diseases, and therapeutic drug development.
Mice with Human Germ Cells
One recurring concern that has been raised about hES
cell-mouse chimeras is that the animals could potentially
generate human germ cells (McLaren, 2007). Although
hES cell-mouse chimeras that have progressed to the
stage of germ cell differentiation have yet to be generated
(James et al., 2006), other types of mice carrying human
germ cells have already been produced. These types of
experiments are designed to investigate the mechanisms
that regulate human germ cell development and to de-
velop ways to preserve the germline of patients (e.g., a pa-
tient undergoing chemotherapy or radiation therapy for
cancer). Initial experiments described the transplantation
of 14–22 gestational week human fetal testis fragments
subcutaneously into nude mice, resulting in the persis-
tence of human gonocytes at 23–57 days posttransplanta-
tion (Povlsen et al., 1974). Nagano et al. (2002) trans-
planted testicular cells from men with obstructive
azoospermia or spermatogenesis maturation arrested by
drug therapy directly into the seminiferous tubules of
nude mice whose endogenous spermatogenesis had
been ablated by the drug busulfan. They found that the
mouse tubules were successfully colonized by the human
spermatogonial stem cells that proliferated and persisted
for up to 6 months posttransplantation. However, the hu-
man spermatogonial stem cells did not progress to meio-
sis. Subcutaneous grafting of testicular tissue fragments
in immune-deficient mice has successfully yielded mature
and functional spermatozoa from diverse mammalian
species (Orwig and Schlatt, 2005). Subcutaneous trans-
plantation of human prepubertal and adult testicular tissue
fragments into immune-deficient mice has also been at-
tempted, showing that human spermatogonia can survive
in mice (Geens et al., 2006). While success with human
testicular tissue has been limited, the subcutaneous trans-
plantation assay has been used to generate fertilization-
competent spermatozoa from prepubertal rhesusmonkey
testicular fragments (Honaramooz et al., 2004). Thus, with
more research it may be possible to incorporate this tool
with strategies to preserve the germline of young boys
undergoing chemo- and radiotherapies that cause
sterilization.
The study of human female germline development and
its preservation has also been pursued using human-
mouse chimeras. Ovary transplantation in the mouse is
a classic method for preserving the germline of female
mutants thatmay have reduced fertility because of comor-
bidity. Adult or even fetal mouse ovaries are transplanted
orthotopically into histocompatible wild-type hosts, re-sulting in the generation of oocytes that can be fertilized
by normal matings to produce progeny. The ovaries
frommany different species of mammals have been trans-
planted into immune-deficient mice, including marsupials,
cow, cat, elephant, and human, yielding antral follicles
(Paris et al., 2004). The utility of the xenograft assay for
preserving the female germline of a mammal was estab-
lished by the production of live mouse young from mouse
ovaries grafted into nude rats (Snow et al., 2002). The cor-
tex of the human ovary contains hundreds of primordial
follicles, and small fragments are amenable for cryopres-
ervation. Frozen and thawed human ovarian fragments
have been transplanted subcutaneously or under the renal
capsule of nude or SCIDmice, yielding antral follicles. This
has allowed the effects of various hormone manipulations
on follicle development to be explored. In one study, cry-
opreserved ovarian fragments from 18 human lymphoma
patients were grafted into SCID mice. None of the recipi-
ent mice developed lymphoma, whereas mice receiving
lymph node tissue from one of the lymphoma patients de-
veloped B cell lymphomas (Kim et al. 2001). This study
suggests that ovarian tissue fragments isolated from
patients prior to treatment for lymphoma could be pre-
screened in human-mouse chimeras prior to autotrans-
plantation to restore fertility.
Human ES Cells Transplanted into Animals
One of the pivotal biological discoveries in recent years
has been the derivation of pluripotent hES cells. hES cell
pluripotency has been screened by in vitro differentiation
assays. In vivo, the predominant assay for pluripotency
has been teratoma formation. Teratoma formation from
hES cells injected subcutaneously into immune-deficient
mice results in a tumor with many, potentially all, differen-
tiated body cell types. Human-mouse chimeras carrying
hES cell-derived teratomas are discussed in depth in
Lensch et al. (2007).
There are only a few reports directly combining hES
cells with the embryos of vertebrate model organisms.
Chick embryos were used as a host to test hES cell po-
tency (Goldstein et al., 2002). Clumps of 100–200 hES
cells were grafted into somite stage embryos and incu-
bated for 1–5 days to create human-chick chimeras. The
transplanted hES cells were able to survive, proliferate,
and differentiate into epithelia, dorsal root ganglia, and
neural rosettes with differentiated human neurons associ-
ated with the host neural tube. There is currently one re-
port describing the results of injection of hES cells into
the cavities of mouse blastocysts (James et al., 2006).
The injected hES cells were incorporated into the inner
cell mass of the blastocysts and continued to express
the pluripotency protein, Oct3/4. Of 28 hES cell-mouse
chimeric blastocysts transferred into the uterus of female
foster mice and collected 5 days later at head-fold stages,
only four embryos had hES cell-derived cells and only one
of the four appeared normal, containing just ten hES cell-
derived cells in foregut endoderm and neuroepithelium. It
is currently unclear why there was such poor incorporation
of the hES cells into the mouse embryo. Finally, hES cellsCell Stem Cell 1, September 2007 ª2007 Elsevier Inc. 261
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mice (Muotri et al., 2005). The hES cells were marked by
enhanced green fluorescent protein (EGFP) expression
and 105 were injected through the exposed uterus into
the lateral ventricles of 14 days postcoitus mouse fetuses
and then returned to the mothers to complete gestation.
Differentiated and functional human neurons and glia
formed that were incorporated into the brains of the host
animal. Interestingly, the size and timing of differentiation
of the human cells appeared to be regulated by the host
environment. In addition, no hES cell-derived teratomas
formed in this human-mouse chimera model. Although
the above examples suggest that hES cells may have re-
markable regenerative potential in embryos and fetuses,
there are currently too few examples of these types of
experiments to make many conclusions.
Human-Animal Chimeras: An Established In Vivo
Paradigm for Biomedical Research
Model organisms offer in vivo systems to study fundamen-
tal biological processes, providing insights into human
physiology. However, these animals are not human and
have limitations for studying specific human cellular char-
acters. Practical and ethical concerns preclude direct
studies on humans. Thus, human-animal chimeras pro-
vide an in vivo system for studying human tissues without
experimentation on human individuals. Most of the biolog-
ical outcomes from the human-animal chimera studies
presented above are no different than what might occur
if hES cells were mixed with animal embryos. As with all
animal experimentation, there must be regulatory over-
sight (see Hyun et al., 2007). However, current discussions
about the potential biological outcomes of hES cell-animal
chimeras should consider the long heritage of human-
animal chimera research that has provided important
insights into human physiology, disease, and drug
discovery.
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